MCRB | tickerfilter.com

Fundamental analysis

25%

Profitability 18%

Dept financing 25%

Liquidity 46%

Performance 27%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-0.53%

1 Month

9.46%

3 Months

15.38%

6 Months

28.00%

1 Year

-28.36%

2 Year

-81.14%

Key data

Stock price

$0.95

P/E Ratio

-0.75

DAY RANGE

$0.95 - $0.95

EPS

-$1.17

52 WEEK RANGE

$0.60 - $2.05

52 WEEK CHANGE

-$31.43

MARKET CAP

121.476 M

YIELD

N/A

SHARES OUTSTANDING

151.731 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

11/05/2024

BETA

1.13

PUBLIC FLOAT

AVERAGE 10 VOLUME

$2,060,975

AVERAGE 30 VOLUME

$2,654,537

Company detail

CEO: Eric D. Shaff
Region: US
Website: serestherapeutics.com
Employees: 330
IPO year: -

Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

Seres Therapeutics, Inc. engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the treatment of clostridium difficile infection. SER-155, a cultivated bacteria microbiome drug, is Phase Ib clinical trial to reduce incidences of gastrointestinal infections, bloodstream infections, and graft versus host diseases.

MCRB - Seres Therapeutics, Inc.